MedTrace Logo

CT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy

NCT05580809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2022-10-17

No results posted yet for this study

Summary

The purpose of this study is to compare CT perfusion parameters to RECIST 1.1 and mRECIST assessment for advanced HCC treated by systemic immunotherapy, and to evaluate perfusion parameters as predictive factors of response on baseline and on early follow-up

Conditions

  • Advanced HCC Treated by Systemic Immunotherapy

Sponsors & Collaborators

  • Valérie LAURENT

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-06-30
Completion
2022-08-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580809 on ClinicalTrials.gov